Acorah Software Products - Accounts Production 16.1.300 false true false true No description of principal activity 1 November 2023 31 October 2024 31 October 2024 15201584 Dr Essam Raweily Mrs Rita Raweily iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 15201584 2023-10-31 15201584 2024-10-31 15201584 2023-11-01 2024-10-31 15201584 frs-core:CurrentFinancialInstruments 2024-10-31 15201584 frs-bus:PrivateLimitedCompanyLtd 2023-11-01 2024-10-31 15201584 frs-bus:FilletedAccounts 2023-11-01 2024-10-31 15201584 frs-bus:Micro-entities 2023-11-01 2024-10-31 15201584 frs-bus:AuditExempt-NoAccountantsReport 2023-11-01 2024-10-31 15201584 frs-bus:Director1 2023-11-01 2024-10-31 15201584 frs-bus:Director2 2023-11-01 2024-10-31
Registered number: 15201584
Er Pathology Holding Company Ltd
Unaudited Financial Statements
For The Year Ended 31 October 2024
Tax Driven Accountants
Balance Sheet
Registered number: 15201584
2024
£
Current assets 25,000
Creditors: Amounts Falling Due Within One Year (27,064 )
NET CURRENT LIABILITIES (2,064 )
TOTAL ASSETS LESS CURRENT LIABILITIES (2,064 )
NET LIABILITIES (2,064 )
CAPITAL AND RESERVES (2,064 )

Notes

1. General Information
Er Pathology Holding Company Ltd is a private company, limited by shares, incorporated in England & Wales, registered number 15201584 . The registered office is Unit 4 Ffordd Richard Davies, St Asaph Business Park, St Asaph, LL17 0LJ.
2. Average Number of Employees
Average number of employees, including directors, during the year was: NIL
-
For the year ending 31 October 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared in accordance with the micro-entity provisions and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
On behalf of the board
Dr Essam Raweily
Director
03/01/2025